Friday 6-6-2014 Advaxis Inc (ADXS) $ADXS opened at 3.21 hitting the high price of 3.33 and a day low of 3.13 with a total volume of 196,900. ADXS had a previous close of 3.21 and has been seeing an average volume of 240,760.
Overall Average: 32% Buy
Recent stock forum discussions about ADXS http://investorshangout.com/search?q=ADXS&...mp;yt0=Go!
Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in Canine Osteosarcoma
GlobeNewswire - Fri Jun 06, 6:29AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator, Nicola Mason, B.Vet. Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, presented updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including canine and human bone cancer and breast cancer. (full story)
3 Stocks Under $10 Making Big Moves
at The Street - Wed Jun 04, 8:12AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Data Published by Researchers at the National Cancer Institute Further Identifies How Advaxis's Lm-LLO Immunotherapy Eradicates Tumors
GlobeNewswire - Wed Jun 04, 7:06AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute (NCI) reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. This research demonstrates the critical role of the tLLO peptide fusion and the strong adjuvant effect of tLLO as contributing to the increase in activated T-cells and the relative decrease in the number of Tregs in tumors, thereby increasing anti-tumor activity. (full story)
Advaxis Presents New Long-Term Survival Data Greater Than 24-Months at ASCO Annual Meeting
GlobeNewswire - Sat May 31, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, presented final results from the Phase 2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in women with recurrent cervical cancer at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. These data showed that ADXS-HPV was well-tolerated and that 22% (24/109) of the patients were long-term survivors (LTS) >18 months. 18% (16/91) of patients were alive for more than 24 months. (full story)
Advaxis Selects inVentiv Health Clinical To Conduct Clinical Trials Of Immunotherapy Candidates
PR Newswire - Thu May 29, 11:57AM CDT
inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. (full story)
Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
GlobeNewswire - Tue May 27, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced that it has been granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-cHER2 for the treatment of osteosarcoma. (full story)
Aratana Therapeutics Reports First Quarter 2014 Results
PR Newswire - Tue May 13, 3:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results. (full story)
Advaxis Principal Investigator to Present ADXS-cHER2 Data in Canine Osteosarcoma at American College of Veterinary Internal Medicine Forum
GlobeNewswire - Tue May 13, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on Thursday, June 5 at 4:25-5:15 p.m.in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma", Dr. Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma. (full story)
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer (full story)
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast (full story)
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer (full story)
Advaxis, Inc. - "Pediatric Osteosarcoma: The First Indication in the ADXS-cHER2 Franchise"
ACCESSWIRE - Wed May 07, 8:56AM CDT
PRINCETON, NJ / ACCESSWIRE / May 7, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. (full story)
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
GlobeNewswire - Mon May 05, 8:42AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In a veterinarian clinical study, pet dogs with naturally occurring osteosarcoma treated with ADXS-cHER2 after the standard of care showed a statistically significant prolonged overall survival benefit compared with dogs that received standard of care without ADXS-cHER2. Both veterinary and human osteosarcoma specialists consider canine osteosarcoma to be the best model for human osteosarcoma. (full story)
Advaxis, Inc. - "3 for 3 on Orphan Drug Requests"
ACCESSWIRE - Mon May 05, 6:51AM CDT
PRINCETON, N.J. / ACCESSWIRE / May 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. (full story)
Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer
GlobeNewswire - Thu May 01, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer. (full story)
Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group
PR Newswire - Wed Apr 30, 1:07PM CDT
The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart, President of The FFF. The grant will allow for the continued coordination and management of this novel clinical trial, representing an important step and sign of promise in anal cancer treatment. (full story)
Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL. (full story)
Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030. (full story)
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register (full story)
Overall Average: 32% Buy
Recent stock forum discussions about ADXS http://investorshangout.com/search?q=ADXS&...mp;yt0=Go!
Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in Canine Osteosarcoma
GlobeNewswire - Fri Jun 06, 6:29AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator, Nicola Mason, B.Vet. Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, presented updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including canine and human bone cancer and breast cancer. (full story)
3 Stocks Under $10 Making Big Moves
at The Street - Wed Jun 04, 8:12AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. (full story)
Data Published by Researchers at the National Cancer Institute Further Identifies How Advaxis's Lm-LLO Immunotherapy Eradicates Tumors
GlobeNewswire - Wed Jun 04, 7:06AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute (NCI) reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. This research demonstrates the critical role of the tLLO peptide fusion and the strong adjuvant effect of tLLO as contributing to the increase in activated T-cells and the relative decrease in the number of Tregs in tumors, thereby increasing anti-tumor activity. (full story)
Advaxis Presents New Long-Term Survival Data Greater Than 24-Months at ASCO Annual Meeting
GlobeNewswire - Sat May 31, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, presented final results from the Phase 2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in women with recurrent cervical cancer at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. These data showed that ADXS-HPV was well-tolerated and that 22% (24/109) of the patients were long-term survivors (LTS) >18 months. 18% (16/91) of patients were alive for more than 24 months. (full story)
Advaxis Selects inVentiv Health Clinical To Conduct Clinical Trials Of Immunotherapy Candidates
PR Newswire - Thu May 29, 11:57AM CDT
inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. (full story)
Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
GlobeNewswire - Tue May 27, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced that it has been granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-cHER2 for the treatment of osteosarcoma. (full story)
Aratana Therapeutics Reports First Quarter 2014 Results
PR Newswire - Tue May 13, 3:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results. (full story)
Advaxis Principal Investigator to Present ADXS-cHER2 Data in Canine Osteosarcoma at American College of Veterinary Internal Medicine Forum
GlobeNewswire - Tue May 13, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on Thursday, June 5 at 4:25-5:15 p.m.in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma", Dr. Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma. (full story)
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer (full story)
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast (full story)
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer (full story)
Advaxis, Inc. - "Pediatric Osteosarcoma: The First Indication in the ADXS-cHER2 Franchise"
ACCESSWIRE - Wed May 07, 8:56AM CDT
PRINCETON, NJ / ACCESSWIRE / May 7, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. (full story)
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
GlobeNewswire - Mon May 05, 8:42AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In a veterinarian clinical study, pet dogs with naturally occurring osteosarcoma treated with ADXS-cHER2 after the standard of care showed a statistically significant prolonged overall survival benefit compared with dogs that received standard of care without ADXS-cHER2. Both veterinary and human osteosarcoma specialists consider canine osteosarcoma to be the best model for human osteosarcoma. (full story)
Advaxis, Inc. - "3 for 3 on Orphan Drug Requests"
ACCESSWIRE - Mon May 05, 6:51AM CDT
PRINCETON, N.J. / ACCESSWIRE / May 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. (full story)
Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer
GlobeNewswire - Thu May 01, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer. (full story)
Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group
PR Newswire - Wed Apr 30, 1:07PM CDT
The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart, President of The FFF. The grant will allow for the continued coordination and management of this novel clinical trial, representing an important step and sign of promise in anal cancer treatment. (full story)
Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL. (full story)
Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030. (full story)
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register (full story)
